Item 5.07. Submission of Matters to a Vote of Security Holders.

Sage Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting") on June 10, 2021. As of April 13, 2021, the record date for the Annual Meeting, there were 58,431,248 outstanding shares of the Company's common stock. The Company's stockholders voted on the following matters, which are described in detail in the Company's Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 29, 2021: (i) to elect three directors, Elizabeth Barrett, Geno Germano and Steven Paul, M.D., as Class I directors of the Company to each serve for a three-year term expiring at the Company's annual meeting of stockholders in 2024 and until his or her successor has been duly elected and qualified, subject to his or her earlier death, resignation or removal; (ii) to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021 and (iii) to hold a non-binding advisory vote to approve the compensation paid to the Company's named executive officers.

At the Annual Meeting, the Company's shareholders voted on the following proposals:

1. The following nominees were elected to the Company's Board of Directors as Class I directors for terms expiring at the 2024 annual meeting of stockholders.





                                                             Broker Non-
Class I Director Nominee       For            Withheld          Votes
Elizabeth Barrett            36,956,421       13,443,633        2,250,291
Geno Germano                 21,417,816       28,982,238        2,250,291
Steven Paul, M.D.            11,092,463       39,307,591        2,250,291

2. The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2021 was ratified.





   For       Against   Abstain   Broker Non-Votes
52,564,179   81,693     4,473           0

3. A non-binding, advisory proposal on the compensation of the Company's named executive officers was approved.





   For        Against     Abstain   Broker Non-Votes
33,691,544   16,696,177   12,333       2,250,291

No other matters were submitted to or voted on by the Company's stockholders at the Annual Meeting.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses